Maxim analyst Allen Klee upgraded CareCloud to Buy from Hold with a $3 price target after its Q4 earnings beat and FY24 guidance. The management’s increased cost-cutting measures should improve free cash flows by $18M, while the company’s revenue drivers include growth in Wellness and medSR, along with new AI products, the analyst tells investors in a research note. Maxim adds that CareCloud currently trades at 7.1-times expected 2025 EBITDA – a deep discount vs. the peer group average of 15.6-times.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCLD:
- CareCloud Enhances Earnings Insight with Supplementary Slides
- CareCloud sees FY24 revenue guidance $118M-$120M, consensus $124.74M
- CareCloud reports Q4 adjusted EPS 5c, consensus (34c)
- CareCloud to showcase generative AI solutions at HIMSS Conference
- CareCloud to Showcase its Generative AI Solutions and Tech-Enabled RCM at the 2024 HIMSS Conference and Exhibition
